Almitrine/Raubasine indications
Treatment of the symptoms of cognitive decline of ischemic origin in elderly patients.
Treatment of the symptoms of neurosensory decline of ischemic origin in elderly patients, including visual and auditory deficit.
Treatment of tinnitus, vertigo and balance disorders of ischemic origin in elderly patients. this Drug belong to the (diphenylmethyl) group
Almitrine/Raubasine description
Almitrine/Raubasine is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Almitrine/Raubasine exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Almitrine/Raubasine interactions
Almitrine/Raubasine may increase the plasma-level of concomitantly given lithium. In order to avoid lithium intoxication, lithium plasma levels should be monitored closely. If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively. Avoid the concomitant use of chlorprothixene and tramadol (Ultram). Massive seizures may be encountered with this combination. Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates. Choose particular low doses of these drugs. Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
Almitrine/Raubasine side effects
Rare side effects have been reported: Weight loss, peripheral neuropathy with abnormal sensations in the lower limbs or paresthesiae (prickling, pins-and-needles, numbness). These effects have usually been observed during the long-term treatment of ≥1 year. These signs disappear following cessation of the treatment. Nausea, heartburns and epigastric heaviness, dyspepsia, disorders of the intestinal transit, sleep disorders eg, insomnia or drowsiness, agitation, anxiety, palpitations, vertiginous sensations.
Almitrine/Raubasine contraindications
Contraindications include alcohol abuse (adds to the central nervous system (CNS) depressant effects), blood disease, enlarged prostate, glaucoma, heart or blood vessel disease, lung disease, Parkinsons disease, stomach ulcers, urination problems (thioxanthenes may worsen the condition), liver disease (higher blood levels of thioxanthenes may occur, increasing the likelihood of side effects), Reyes syndrome (the risk of liver problems may be increased), and seizure disorders (the risk of seizures may be increased).
Active ingredient matches for Almitrine/Raubasine:
Almitrine/Raubasine
List of Almitrine/Raubasine substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Albasine (Bangladesh) | |
| Dumazil (Vietnam) | |
| Dumazil 2 Blister x 15 Tablet | |
| Duxaril (Hong Kong, Philippines, Singapore, Thailand) | |
| Duxaril 30's (Servier) | $ 28.89 |
| Duxor (Spain) | |
| Premodal (Lithuania) | |
| Pyducil (Vietnam) | |
| Pyducil 3 Blister x 10 Tablet | |
| Pymeducil (Vietnam) | |
| Salvalion (Spain) | |
| Transoxyl (Portugal) | |
| Truxil (Bangladesh) | |
References
- PubChem. "ALMITRINE". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "ALMITRINE". http://www.drugbank.ca/drugs/DB01430 (accessed September 17, 2018).
- MeSH. "Respiratory System Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Almitrine/Raubasine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Almitrine/Raubasine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
| Users | % | ||
|---|---|---|---|
| > 60 | 1 | 50.0% | |
| 30-45 | 1 | 50.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
